Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cell-based therapies for the treatment of perianal Crohn’s disease have well-established safety profiles and improved efficacy compared with conventional therapy. However, stem cells are not a homogeneous product and questions remain before we can optimize clinical trials of these treatments and achieve best patient outcomes.
Work during the past two decades has highlighted how HIV contributes to hepatic inflammation and fibrosis, leading to changes in the timing of antiretroviral therapy initiation and to improved diagnosis and management of liver disease in patients with HIV. As this population ages, clinician vigilance with early detection of emerging liver disease will be critical.
Obesity is an established risk factor for gastrointestinal cancers. Interventions that reduce the burden of obesity at both the societal and individual level and targeted interventions among those at higher risk of cancer should be developed, supported by advances in understanding of the biology that underpins the obesity–cancer link.
Bariatric surgery-induced weight loss is associated with reduced overall cancer incidence; however, some data suggest that risk of colorectal cancer (CRC) actually increases. Here, we suggest a need to fully characterise CRC (and colorectal adenoma) risk after bariatric surgery given that preventive measures (early diagnosis and polypectomy) can mitigate risk.
This Poster illustrates the current epidemiology, clinical management and novel treatment targets of hepatitis B, a disease responsible for a large global burden of liver cirrhosis and cancer.